The efficiency and safety of using the gonadotropin-releasing hormone agonist Buserelin-long FS in late reproductive-aged patients with endometriosis: A clinical trial
article
OA: closed
CC0
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This clinical trial evaluated the efficiency and safety of Buserelin-long FS, a gonadotropin-releasing hormone agonist, for treating endometriosis in women of late reproductive age.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density 2014
- An Overview of Treatments for Endometriosis 2015
- Gonadotropin-Releasing Hormone Analogues Reduce the Proliferation of Endometrial Stromal Cells but Not Endometriotic Cells 2012
References (5)
- An Overview of Treatments for Endometriosis via openalex
- Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density via openalex
- Gonadotropin-Releasing Hormone Analogues Reduce the Proliferation of Endometrial Stromal Cells but Not Endometriotic Cells via openalex
- W2128826057 via openalex
- W2163315477 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK